eligibility_summary
Eligible: B-ALL patients ≥16 with both pre- and post-transplant disease status documented. Exclude: prior blinatumomab >14 days, pre-treatment leukemia burden ≥10%, severe organ dysfunction (e.g., MI, chronic heart failure, decompensated liver, renal, or GI dysfunction), or CNS leukemia.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: Blinatumomab, a bispecific T‑cell engager (BiTE) antibody construct, given short-term (8→28 μg/day over 5–10 days) as a bridge to allo-HSCT in low-burden B-ALL. Mechanism: Blinatumomab binds CD19 on B‑cell lymphoblasts and CD3 on T cells, forming an immune synapse that activates TCR/CD3 signaling and redirects cytotoxic T cells to lyse CD19+ leukemia cells (perforin/granzyme-mediated apoptosis). Dexamethasone (glucocorticoid) is used as premedication to mitigate cytokine release by suppressing inflammatory cytokine transcription. Targets: CD19+ malignant B cells, T-cell CD3/TCR pathway and downstream cytotoxic machinery, inflammatory cytokine pathways (CRS mitigation).